A product can contain the intended valuable constituent while also carrying material that affects acceptance or treatment terms. For an owner, the decision is whether the test programme and commercial assumptions have identified those characteristics early enough to influence the process. Investors should read product analyses alongside the proposed pricing mechanism, rather than focus on the headline recovery.
Define the complete product
The technical specification should identify relevant chemical and physical attributes, with suitable analytical methods and sample provenance. CIM's processing guidance explicitly addresses contaminants that may attract penalties or affect economic value. The owner should seek the information appropriate to the intended market. A hypothetical concentrate with a favourable main-metal grade may still require additional evaluation because another constituent changes downstream treatment. The journal cannot determine the consequence for an actual product without its specification and commercial terms. The development file should make that uncertainty visible and state which analyses or customer tests are needed next.
Connect quality to a credible buyer discussion
The commercial team should distinguish a preliminary conversation from formal qualification and a purchase commitment. Each can provide useful information, but they establish different things. Proposed limits, adjustments and rejection conditions need documentary support appropriate to the study stage. JORC's marketing considerations provide a broad reporting reference. Investors should ask who supplied the assumed terms and what product description was presented. A quotation based on a cleaner or differently prepared sample cannot automatically support the material currently modelled. The technical and commercial teams need a shared, dated description of the output being evaluated.
Test the cost of changing the product
A process modification intended to improve quality may alter recovery, energy, reagent demand or waste streams. The owner should compare integrated alternatives rather than assume a cleaner product is available without consequence. Those comparisons require appropriate specialist work and consistent feed. A hypothetical additional separation stage could improve one attribute while reducing overall recovery. The resulting commercial case should carry both changes through the model. Investors can then see whether the adjustment improves the accepted product's contribution under the assumed terms and which uncertainties remain before selecting a more complex processing route or additional capital equipment.
Preserve variability in revenue assumptions
Quality can vary with the feed and operating conditions. A single product sample may leave difficult periods unresolved. The proposed schedule should identify whether different material could change acceptance, pricing or the need for blending. Owners should avoid replacing that variation with the best observed product analysis. Investors should examine sensitivities grounded in plausible technical evidence rather than arbitrary discounts. A defensible revenue line is supported by a consistent chain from feed through tested process to defined product and appropriate commercial terms. The impurity discussion belongs in that chain before a headline value is multiplied across a conceptual production schedule.
